Supplier News: Simtra, CordenPharma, CoreRx & More
The latest from CDMOs, CMOs, and suppliers featuring Simtra BioPharma Solutions, CordenPharma, CoreRx, Societal CDMO, Ritedose, and Experic.
Formulation Development/Drug Product Manufacturing
* Simtra BioPharma To Invest $250 M In Sterile Fill-Finish Mfg Facility Expansion
* CoreRx To Acquire Societal CDMO For $130 M
* Ritedose Investing $81 M for Sterile Mfg Expansion
* CordenPharma Launches Lipid NanoParticle Kits for mRNA Formulation
* Experic To Expand Clinical Storage & Logistics Depot
Formulation Development/Drug Product Manufacturing
Simtra BioPharma To Invest $250 M In Sterile Fill-Finish Mfg Facility Expansion
Simtra BioPharma Solutions, a CDMO of injectables, has announced a $250-million expansion of its sterile fill–finish manufacturing campus in Bloomington, Indiana.
A new 150,000-square-foot building will be constructed to house two high-speed automated isolator syringe fill lines and a new high-speed isolator vial line equipped with three 30-square meter lyophilizers. Each process suite in the new building will be fitted with dedicated formulation/compounding rooms.
The expansion will also include the addition of a dedicated clinical line equipped to support the company’s growing development/clinical business. The clinical line is expected to be ready to onboard new projects by the summer of 2025. Construction of the new building is planned to begin in June 2024 and is anticipated to take two years to complete to allow for GMP readiness in late 2026.
Source: Simtra BioPharma Solutions
CoreRx To Acquire Societal CDMO For $130 M
CoreRx, a Clearwater, Florida-based CDMO of drug products, has agreed to acquire Societal CDMO, a Gainesville, Georgia-based CDMO of drug products, for $130 million.
Under the agreement, CoreRx will commence a cash tender offer to acquire all outstanding shares of Societal CDMO common stock for $1.10 per share in cash, subject to applicable tax withholding, and Societal CDMO has agreed to file a recommendation statement containing the unanimous recommendation of its Board of Directors that Societal CDMO shareholders tender their shares to CoreRx.
The transaction is expected to close early in the second quarter of 2024, and is subject to the tender of a majority of the outstanding shares of Societal CDMO’s common stock, as well as other customary closing conditions. Following the successful closing of the tender offer, CoreRx will acquire all remaining shares of Societal CDMO that are not tendered into the tender offer through a second-step merger at the same price of $1.10 per share, without the vote of Societal CDMO shareholders. The merger will be effected as soon as practicable after the closing of the tender offer. Until that time, Societal CDMO will continue to operate as a separate and independent company.
Source: Societal CDMO
Ritedose Investing $81 M for Sterile Mfg Expansion
The Ritedose Corporation, a CDMO of drug products, has announced a purchase of 105 acres of land in Richland Northeast, South Carolina, as part of a capital expansion plan.
The expansion is part of a multi-phased project totaling more than $81 million over four years. When complete, the campus will house nearly 500,000 square feet of space dedicated to the manufacturing, packaging, and distribution of pharmaceuticals.
The first building on the newly acquired property will be a 225,000-square-foot central distribution and logistics center. The company plans to break ground in early March (March 2024).
Source: Ritedose
CordenPharma Launches Lipid NanoParticle Kits for mRNA Formulation
CordenPharma has launched Lipid NanoParticle (LNP) Starter Kits for mRNA formulation used in the development of mRNA-based therapeutics such as mRNA vaccines or gene therapies.
The LNP Kits consist of both well-known and characterized formulations in a preclinical and clinical setting, with various combinations available to benchmark / compare LNP formulations or create compositions.
Source: CordenPharma
Experic To Expand Clinical Storage & Logistics Depot
Experic, a Cranbury, New Jersey-based CDMO of drug products, has announced a new facility in Dublin, Ireland, to support global clinical trials.
The 10,000-square-foot warehouse space will provide monitored storage and logistics services, including cold storage and re-labeling capabilities, for the distribution of investigational medicinal products and comparators for pharmaceutical companies conducting global clinical trials with investigator sites and patients across Europe. The facility is set to open in the second half of 2024.
Source: Experic
